Skip to main
ONCY
ONCY logo

ONCY Stock Forecast & Price Target

ONCY Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Oncolytics Biotech Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative cancer therapeutics, particularly highlighting its lead product, pelareorep, which enhances the immune system's capability to combat cancer and may become a foundational immunotherapy for specific breast cancer types. The potential for strategic partnerships is significant, as such collaborations could extend the company's operational runway and enable the progression of pelareorep towards regulatory approval, thereby unlocking substantial value for shareholders. Additionally, external validation from key opinion leaders reinforces Oncolytics’ reputation and strengthens its position to secure these partnerships, enhancing the overall outlook for the company's future growth and market presence.

Bears say

Oncolytics Biotech Inc. is in the clinical-stage of its biopharmaceutical development, focusing on treatments for various cancers but currently lacks proven revenue-generating products, which raises concerns about its financial stability. The company’s pipeline consists primarily of experimental therapies, with the lengthy development timelines and inherent risks associated with clinical trials contributing to its uncertainty in achieving successful outcomes. Additionally, recent financial reports indicate rising operational costs without offsetting revenues, leading to concerns about Oncolytics Biotech's ability to sustain its operations and funding for ongoing projects.

ONCY has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Oncolytics Biotech, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Oncolytics Biotech, Inc. (ONCY) Forecast

Analysts have given ONCY a Strong Buy based on their latest research and market trends.

According to 4 analysts, ONCY has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Oncolytics Biotech, Inc. (ONCY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.